Kim, Hyondeog Lee, Wonyeop Kim, Youngwook Lee, Sang-Jin Choi, Wonyoung Lee, Geon Kook Park, Seung-Jin Ju, Shinyeong Kim, Seon-Young Lee, Cheolju Han, Ji-Youn 2024-10-02T09:30:31Z 2024-10-02T09:30:31Z 2024-10-02 2024-09 1226-3613 https://pubs.kist.re.kr/handle/201004/150694 Patients with lung adenocarcinoma who have never smoked (NSLA) and lack key driver mutations, such as those in the EGFR and ALK genes, face limited options for targeted therapies. They also tend to have poorer outcomes with immune checkpoint inhibitors than lung cancer patients who have a history of smoking. The proteogenomic profile of nonsmoking lung adenocarcinoma patients without these oncogenic driver mutations is poorly understood, which complicates the precise molecular classification of these cancers and highlights a significant area of unmet clinical need. This study analyzed the genome, transcriptome, and LC-MS/MS-TMT-driven proteome data of tumors obtained from 99 Korean never-smoker lung adenocarcinoma patients. NSLA tumors without EGFR or ALK driver oncogenes were classified into four proteogenomic subgroups: proliferation, angiogenesis, immune, and metabolism subgroups. These 4 molecular subgroups were strongly associated with distinct clinical outcomes. The proliferation and angiogenesis subtypes were associated with a poorer prognosis, while the immune subtype was associated with the most favorable outcome, which was validated in an external lung cancer dataset. Genomic-wide impacts were analyzed, and significant correlations were found between copy number alterations and both the transcriptome and proteome for several genes, with enrichment in the ERBB, neurotrophin, insulin, and MAPK signaling pathways. Proteogenomic analyses suggested several targetable genes and proteins, including CDKs and ATR, as potential therapeutic targets in the proliferation subgroup. Upregulated cytokines, such as CCL5 and CXCL13, in the immune subgroup may serve as potential targets for combination immunotherapy. Our comprehensive proteogenomic analysis revealed the molecular subtypes of EGFR- and ALK-wild-type NSLA with significant unmet clinical needs. English Springer Nature Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma Article 10.1038/s12276-024-01320-0 1 Experimental & Molecular Medicine, v.56, no.9, pp.2082 - 2095 Experimental & Molecular Medicine 56 9 2082 2095 Y scie scopus kci 001316710200001 2-s2.0-85204293521 Biochemistry & Molecular Biology Medicine, Research & Experimental Biochemistry & Molecular Biology Research & Experimental Medicine Article IMMUNE CHECKPOINT INHIBITORS CANCER ANGIOGENESIS MUTATIONS CELLS